Sofosbuvir tablets, an NS5B polymerase inhibitor, target hepatitis C virus RNA replication in combination therapies. Administered by infectious disease specialists in hepatology units of healthcare facilities. Procured through global pharmaceutical supply chains for viral treatment protocols.